Silkis/Vectical
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Analyst Outlook
Silkis/Vectical’s (calcitriol; Horizon Pharma/Galderma) more favorable side-effect profile compared to
calcipotriol-based vitamin D brands Dovobet (calcipotriol/betamethasone; Leo Pharma/Kyowa Hakko
Kirin) and Dovonex (calcipotriol; Leo Pharma), alongside the fact that it contains a naturally occurring
vitamin D derivative, boosts its clinical attractiveness; however, dermatologists are unconvinced by its
efficacy. Indeed, interviewed key opinion leaders indicate their limited usage of Silkis/Vectical,
highlighting that they do not see any advantages in prescribing it over the calcipotriol-based
products.
Drug Overview
Silkis/Vectical contains the active ingredient calcitriol, a biologically active form of vitamin D3.
Silkis/Vectical is available as a topical ointment, which reduces excessive skin cell production and
helps to improve the symptoms of psoriasis. It is sold under the brand name Silkis in Europe and was
launched in the US as Vectical in February 2009, following its approval by the US Food and Drug
Administration for the treatment of mild to moderate plaque psoriasis in adults aged 18 years and
older (Galderma, 2009).
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Silkis/Vectical : Psoriasis
LIST OF FIGURES
6 Figure 1: Silkis/Vectical for psoriasis – SWOT analysis
7 Figure 2: Datamonitor Healthcare’s drug assessment summary of Silkis/Vectical in psoriasis
8 Figure 3: Datamonitor Healthcare’s drug assessment summary of Silkis/Vectical in psoriasis
LIST OF TABLES
4 Table 1: Silkis/Vectical drug profile
5 Table 2: Silkis/Vectical pivotal trial data in psoriasis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sorilux 
Sign up to the